MAPT and Alzheimer disease: Given the repeated failures of trials targeting the Aβ pathway in mild or moderate AD [4], there is increasing interest in the possibility that tau-targeted compounds could have therapeutic utility in AD, particularly tau aggregation inhibitors (TAIs) [5, 7, 8].